Prevention of Asthma Relapse After Discharge From Emergency

A Comparison of Budesonide/Formoterol Turbuhaler® 160/4.5 µg 2 Inhalations BID Plus as Needed to Budesonide Turbuhaler® 320 µg 2 Inhalations BID Plus Terbutaline Turbuhaler® 0.4 mg as Needed for the Prevention of Asthma Relapse

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00326053

Acronym

PARADE

Enrollment

600

Registered

2006-05-16

Start date

2006-05-31

Completion date

2007-05-31

Last updated

2011-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Asthma Reoccurrence, Acute Asthma, Patient Discharge, Emergency Service, Hospital, Asthma Exacerbation, Asthma Relapse

Brief summary

The purpose of this study is to compare the Symbicort® Turbuhaler® to both Pulmicort® Turbuhaler® and Bricanyl® Turbuhaler® for the treatment of asthma after discharge from the emergency room

Interventions

DRUGBudesonide/formoterol

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* 18 - 65 years of age * Presenting at a study emergency department with an asthma exacerbation

Exclusion criteria

* Admission to hospital * Patients receiving more than 2000 µg/day of beclomethasone equivalent inhaled corticosteroids (1000 µg/day fluticasone or 1600 µg/day budesonide)

Design outcomes

Primary

Measure	Time frame
Time to first asthma relapse	—

Secondary

Measure	Time frame
Mean use of reliever medication	—
Asthma Control Questionnaire (ACQ) score	—
Complete AE and SAE collection	—

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026